Survival in heart failure
Introduction
- Heart failure (HF) is an enormous public health burden with 300,000 new deaths each year and a prevalence of 6.5 million people in the United States1.
- There is large variability in HF prognosis2, and there is a need for a broader systemic approach to identify novel circulating markers of HF progression.
- One of the most robust and validated models for mortality prediction in HF patients is the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score3.
- Additionally, the use of N-Terminal pro-B-Type Natriuretic Peptide (NTproBNP) has been shown to be valuable in prognosis prediction4.
- It is uncertain if the plasma proteome is a better prediction tool for the course of HF compared to the clinical risk score MAGGIC and NTproBNP.
Learn more by downloading this poster
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.